Latest news for Mesoblast (OTC:MEOBF) Stock

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Cannabis

News

Penny Stocks

Psychedelics

Small Cap

Markets

AVTX

HALO

MEOBF

MNMD

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

MindMed Appoints Schond L. Greenway As CFO

Mesoblast Ltd

Mesoblast

Mind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.

&ldquo;We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech capital markets, which was a key attribute we sought in identifying a CFO,&rdquo; stated Robert Barrow, CEO and director of MindMed. &ldquo;Schond is joining MindMed at an exciting point in our growth, with numerous near-term milestones ahead across our pipeline. I look forward to working closely with him to advance our mission of becoming a global leader in the development of innovative therapies for brain health disorders.&rdquo;

Greenway joins MindMed after serving as CFO of Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>), a precision medicine clinical stage bio-pharmaceutical company. He previously served as VP of investor relations at Mesoblast (OTCPK:MEOBF), an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) and in various roles at investment banking firms Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) and Barclays Capital, predominantly focused on healthcare and technology.

Photo: Courtesy of <a href="https://unsplash.com/@cytonn_photography?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Cytonn Photography</a> on <a href="https://unsplash.com/s/photos/handshake?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Related News

<a href="https://www.benzinga.com/general/biotech/22/05/27303544/mindmed-reports-promising-results-for-non-hallucinogenic-ibogaine-congener-substance" target="_blank">MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance</a>

<a href="https://www.benzinga.com/markets/cannabis/22/05/27227735/mindmed-reports-financial-results-for-q1-with-lower-cash-balance-compared-to-december-last-year" target="_blank">MindMed Reports Financial Results For Q1, With Lower Cash Balance Compared To December Last Year</a>

<a href="https://www.benzinga.com/general/biotech/22/05/27168268/can-lsd-treat-anxiety-this-new-clinical-topline-data-by-mindmed-is-very-promising" target="_blank">Can LSD Treat Anxiety? MindMed&#39;s New Topline Data Show Promise, Here&#39;s The Research</a>

&nbsp;

Comments

Mesoblast

News

Latest news for Mesoblast (OTC:MEOBF) Stock

Monday, May 23, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga